AVEO Oncology and EUSA Pharma announce TiNivo combination study Opt-in
AVEO Oncology announced that EUSA Pharma has opted into the Phase 1/2 TiNivo study. EUSA may utilize data from the study for regulatory or commercial purposes in exchange for a research and development funding payment totaling $2.0 million. September 20, 2017